Monitor the outcome of shareholder votes on April 23, 2026; approval of the omnibus plan and quorum amendment is expected. The quorum increase reduces the risk of failed meetings and supports Nasdaq continued listing. No trading catalyst from this filing alone.
Price Chart
Executive Summary
NervGen Pharma filed a management proxy circular for its April 23, 2026 annual general meeting, seeking shareholder approval on routine governance matters including director elections, auditor appointment, a new omnibus equity incentive plan (up to 3 million shares), amendments to the stock option plan, and an increase in the quorum requirement from 5% to 33⅓% to comply with Nasdaq rules after losing FPI status in January 2027. No financial results or material business developments were disclosed; the filing is standard procedural governance.
Key Facts
- Annual meeting set for April 23, 2026 with record date March 13, 2026.
- Board proposes to set number of directors at 8 for the ensuing year.
- New 2026 Equity Incentive Plan (Omnibus Plan) authorizes up to 3 million shares, plus annual evergreen increases from 2027-2036.
- Stock Option Plan amendments add net exercise and cashless exercise features.
- Articles to be amended to increase quorum requirement from 5% to 33⅓% to comply with Nasdaq rules; company expects to lose FPI status in January 2027.
- KPMG LLP nominated as auditor for 2026.
- Executive compensation details disclosed: CEO Adam Rogers received $181,000 in option-based awards for 2025; former CEO Michael Kelly received total compensation of $1,667,567 for 2025.
- Insider holdings: PFP Biosciences Holdings LLC beneficially owns 18.2% of outstanding shares.
- Outstanding shares: 80,630,871 as of March 13, 2026.
Financial Impact
No immediate financial impact; potential dilution from up to 3M new shares under omnibus plan is modest (~3.7% of current shares outstanding).
Risk Factors
- Shareholder disapproval of equity plan or quorum amendment could delay governance improvements.
- Evergreen provision in omnibus plan may lead to future dilution beyond initial 3 million shares.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-049508 |
| Document: tm2612795d1_ex10-3.htm | 0001104659-26-049508 |
| Document: tm2612795d1_ex3-1.htm | 0001104659-26-049508 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 6-K | $1.88 $1.81 | ▲ +3.72% | ▲ +4.93% | $1.42 (+24.47%) |
Sep 25, 2026 4w ago | Press Release | $1.88 $1.81 | ▼ −3.72% | ▼ −4.93% | $1.42 (−24.47%) |
Sep 24, 2026 4w ago | 6-K | $2.02 $1.76 | ▼ −12.87% | ▼ −12.46% | $1.42 (−29.70%) |
Aug 13, 2026 10w ago | 6-K | $1.76 $1.76 | · 0.00% | ▲ +1.96% | $1.42 (−19.32%) |
Aug 13, 2026 10w ago | Press Release | $1.76 $1.76 | · 0.00% | ▲ +1.96% | $1.42 (−19.32%) |
Jul 2, 2026 16w ago | 6-K | $2.12 $1.86 | ▲ +12.26% | ▲ +13.19% | $1.42 (+33.02%) |
Jun 1, 2026 21w ago | 6-K | $2.00 $1.81 | ▲ +9.50% | ▲ +6.54% | $1.42 (+29.00%) |
May 27, 2026 21w ago | EFFECT | $2.07 $1.91 | ▼ −7.73% | ▼ −8.20% | $1.42 (−31.40%) |
May 26, 2026 21w ago | 6-K | $2.07 $2.00 | ▼ −3.38% | ▼ −4.59% | $1.42 (−31.40%) |
May 22, 2026 22w ago | 6-K | $2.13 $2.00 | ▲ +6.10% | ▲ +7.32% | $1.42 (+33.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers